[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100381651":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":40,"collaborators":44,"id":53,"slug":7,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":7,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":7,"maxAge":7,"enrollmentInfo":59,"targetDuration":7,"studyType":62,"phases":7,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"University of British Columbia","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Bruce Carleton, PharmD.","CONTACT","604-875-2179","bcarleton@popi.ubc.ca",[15,30],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"cosmosGeoPoint":22,"geoPoint":27,"contacts":28},"Children's and Women's Health Centre of British Columbia","RECRUITING","Vancouver","British Columbia","V6H 3V4","Canada",{"type":23,"coordinates":24},"Point",[25,26],-123.11934,49.24966,{"lat":26,"lon":25},[29],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"facility":31,"status":17,"city":32,"state":33,"zip":34,"country":21,"cosmosGeoPoint":35,"geoPoint":39,"contacts":7},"Children's Hospital of Eastern Ontario","Ottawa","Ontario","K1H 8L1",{"type":23,"coordinates":36},[37,38],-75.69812,45.41117,{"lat":38,"lon":37},{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Bruce Carleton","Director, Pharmaceutical Outcomes Programme",[45,48,50],{"name":46,"class":47},"Genome British Columbia","INDUSTRY",{"name":49,"class":6},"Genome Canada",{"name":51,"class":52},"Dynacare Laboratories, Inc.","UNKNOWN","100381651",false,"NCT04249375","Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System","Inclusion Criteria:\n\n* Participants will be enrolled if they can benefit from pharmacogenomic testing. This means their physician is considering the use of a drug that is part of the panels (analgesics, antibiotics, and mental health medication) or they are already using one.\n\nExclusion Criteria:\n\n* Patients who do not speak or understand English.","ALL",{"count":60,"type":61},150,"ESTIMATED","OBSERVATIONAL","This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications.\n\nWe will conduct pilot testing of a pharmacogenomic testing panel and study how the tests and generated test results are utilized and understood by physicians, pharmacists, patients and their families.",[65],"Adverse Drug Reaction (ADR)",[67,68,69],"Pharmacogenomics","Pediatrics","Adverse Drug Reactions","2026-04-27",{"date":72,"type":73},"2026-05-01","ACTUAL",{"date":75,"type":73},"2020-02-20",{"date":77,"type":61},"2028-03",{"name":5,"class":6},2]